Latest News

States are rationing HIV medications through prior auth and formulary cuts to solve ADAP budget crises — a strategy that costs more, drives resistance, and concentrates harm on the most vulnerable.

Florida ADAP cuts eligibility from 400% to 130% FPL, threatening 16,000 PLWHA.

HIV care system deterioration from administrative obstruction and funding delays presages catastrophic effects of potential budget cuts.

Federal policy changes including Medicaid work requirements and ADAP eligibility restrictions threaten access to HIV medications.

Impending HIV care crisis results from Medicaid work requirements, federal funding cuts, and healthcare system fragmentation.

Historical redlining policies correlate with current geographic disparities in HIV treatment access and care quality.

HHS budget proposal would eliminate critical HIV prevention funding and reduce Ryan White HIV/AIDS program resources.

Long-acting injectable HIV treatments demonstrate clinical promise but face coverage and implementation barriers.

Critical role of mental health services in HIV treatment and epidemic control.

Innovative approaches to improve HIV care transitions for people exiting incarceration.

ADAP coverage gaps for long-acting injectable HIV treatments and equity implications.

Barriers to HIV care for formerly incarcerated people and continuity strategies.

Integrated care models combining HIV treatment and gender-affirming healthcare.

Research on elevated cancer risks in PLWHA and importance of early detection.

PLWHA face elevated cancer risks; screening, HPV vaccination, and coordinated care are critical.

OIG report: 27% of Medicaid HIV enrollees lack evidence of critical services; state disparities exposed.

Australian study: 1% viral load suppression increase correlates with 6% decrease in HIV diagnoses.

Place-based sexual health care in community venues advances HIV/HCV prevention and testing outreach.

Provider language shows negative bias toward Black patients at 2.5x rate, undermining care engagement.

European Commission approves lenacapavir, a novel six-month injectable for treatment-resistant HIV.